Kura Oncology, Inc. filed a current report on September 8, 2026, disclosing the appointment of Jennifer Fulk as Chief Financial Officer, principal financial officer, and principal accounting officer, effective that same date.
Key Highlights
- New CFO appointed: Jennifer Fulk, age 49, was appointed Chief Financial Officer, principal financial officer, and principal accounting officer of Kura Oncology, effective September 8, 2026.
- Predecessors replaced: Fulk replaces Troy E. Wilson, Ph.D., J.D. as principal financial officer and Thomas Doyle as principal accounting officer, according to the filing.
- Base salary: Fulk is entitled to an annual base salary of $550,000 under her employment agreement.
- Equity grants: Fulk is entitled to an option to purchase 450,000 shares of common stock vesting over 4 years, and a performance-based restricted stock unit award covering 173,438 shares vesting in six installments tied to specified milestones.
- Annual bonus eligibility: Fulk is eligible to receive an annual discretionary bonus of up to 45% of her then-current base salary.
- Severance terms: Outside a Corporate Transaction window, termination without Cause or resignation for Good Reason entitles Fulk to 12 months of base salary and up to 12 months of COBRA premiums; within 59 days before or 18 months after a Corporate Transaction closing, those amounts increase to 18 months of base salary plus 150% of her target bonus and up to 18 months of COBRA premiums, with full equity acceleration.
Jennifer Fulk's Background and Compensation Terms at Kura Oncology
According to the filing, Kura Oncology's Board of Directors appointed Jennifer Fulk as CFO effective September 8, 2026. Before joining Kura, Fulk served as Chief Financial Officer of Soleno Therapeutics, Inc. from March 2026 to May 2026, and as Chief Operating Officer and Chief Financial Officer of 120Water, Inc. from September 2024 to October 2025. She also served as Chief Financial Officer of Talkspace, Inc., which the filing describes as "a publicly traded virtual behavioral healthcare company," from July 2021 to May 2024. Prior to those roles, she spent more than 15 years at Eli Lilly and Company in finance executive positions, including as Chief Financial Officer for U.S. Bio-Medicines, Vice President of Investor Relations, and Chief Financial Officer for Lilly Germany, Austria, and Switzerland. The filing states she earned a Bachelor of Science in Information Systems and a Master of Business Administration from Indiana University.
Under the employment agreement dated September 8, 2026, the company disclosed that the stock option grant covering 450,000 shares vests over a 4-year period: 25% vests on the one-year anniversary of the vesting commencement date, with 1/48th of the shares vesting monthly thereafter. The 173,438-share performance-based restricted stock unit award vests in six installments based on the achievement of net product revenue, clinical development, and regulatory approval milestones as determined by the Board. Vesting of all equity awards is subject to Fulk's continuous service with the company.
The filing also states that Fulk's employment is at-will and may be terminated at any time by either party with or without cause and without notice. The filing further discloses that Fulk has no family relationships with any of the company's directors or executive officers, and no direct or indirect material interest in any transaction required to be disclosed under Item 404(a) of Regulation S-K. Kura Oncology's common stock trades on NASDAQ:KURA under the ticker KURA on The Nasdaq Global Select Market.
What Was Disclosed
Kura Oncology disclosed the appointment of Jennifer Fulk as CFO, principal financial officer, and principal accounting officer, along with the full terms of her employment agreement, including salary, equity awards, bonus eligibility, and severance arrangements, in a current report dated September 8, 2026.



Please wait processing your request...